An anonymous reader quotes a report from the Associated Press: Filmmaker Peter Jackson owns one of the largest private collections of bones of an extinct New Zealand bird called the moa. His fascination with the flightless ostrich-like bird has led to an unusual partnership with a biotech company known for its grand and controversial plans to bring back lost species. On Tuesday, Colossal Biosciences announced an effort to genetically engineer living birds to resemble the extinct South Island giant moa -- which once stood 12 feet (3.6 meters) tall -- with $15 million in funding from Jackson and his partner Fran Walsh. The collaboration also includes the New Zealand-based Ngai Tahu Research Centre. "The movies are my day job, and the moa are my fun thing I do," said Jackson. "Every New Zealand schoolchild has a fascination with the moa."

The moa had roamed New Zealand for 4,000 years until they became extinct around 600 years ago, mainly because of overhunting. A large skeleton brought to England in the 19th century, now on display at the Yorkshire Museum, prompted international interest in the long-necked bird. Unlike Colossal's work with dire wolves, the moa project is in very early stages. It started with a phone call about two years ago after Jackson heard about the company's efforts to "de-extinct" -- or create genetically similar animals to -- species like the woolly mammoth and the dire wolf. Then Jackson put Colossal in touch with experts he'd met through his own moa bone-collecting. At that point, he'd amassed between 300 and 400 bones, he said.

In New Zealand, it's legal to buy and sell moa bones found on private lands, but not on public conservation areas -- nor to export them. The first stage of the moa project will be to identify well-preserved bones from which it may be possible to extract DNA, said Colossal's chief scientist Beth Shapiro. Those DNA sequences will be compared to genomes of living bird species, including the ground-dwelling tinamou and emu, "to figure out what it is that made the moa unique compared to other birds," she said. [...] The direction of the project will be shaped by Mori scholars at the University of Canterbury's Ngi Tahu Research Centre. Ngi Tahu archaeologist Kyle Davis, an expert in moa bones, said the work has "really reinvigorated the interest in examining our own traditions and mythology."

An anonymous reader quotes a report from Wired: Trey had struggled with alcoholism for 15 years, eventually drinking heavily each night before quitting in December. But staying sober was a struggle for the 36-year-old first responder from Atlanta, who did not wish to use his real name due to professional concerns. Then he discovered Alterd, an AI-powered journaling app that invites users to "explore new dimensions" geared towards psychedelics and cannabis consumers, meditators, and alcohol drinkers. In April, using the app as a tripsitter -- a term for someone who soberly watches over another while they trip on psychedelics to provide reassurance and support -- he took a huge dose of 700 micrograms of LSD. (A typicalrecreational doseis considered to be 100 micrograms.) "I went from craving compulsions to feeling true freedom and not needing or wanting alcohol," he says.

He recently asked the app's "chat with your mind" function how he had become more wise through all his AI-assisted psychedelic trips. It responded: "I trust my own guidance now, not just external rules or what others think. I'm more creative, less trapped by fear, and I actually live by my values, not just talk about them. The way I see, reflect, and act in the world is clearer and more grounded every day." "It's almost like your own self that you're communicating with," says Trey, adding he's tripped with his AI chatbot about a dozen times since April. "It's like your best friend. It's kind of crazy." The article mentions several different chatbot tools and AI systems that are being used for psychedelic therapy.

ChatGPT: "Already, many millions of people are using ChatGPT on a daily basis, and the developments may have helped democratize access to psychotherapy-style guidance, albeit in a dubious Silicon Valley style with advice that is often flush with untruths," reports Wired. The general-purpose AI chatbot is being used for emotional support, intention-setting, and even real-time guidance during psychedelic trips. While not designed for therapy, it has been used informally as a trip companion, offering customized music playlists, safety reminders, and existential reflections. Experts caution that its lack of emotional nuance and clinical oversight poses significant risks during altered states.

Alterd: Alterd is a personalized AI journal app that serves as a reflective tool by analyzing a user's entries, moods, and behavior patterns. Its "mind chat" function acts like a digital subconscious, offering supportive insights while gently confronting negative habits like substance use. Users credit it with deepening self-awareness and maintaining sobriety, particularly in the context of psychedelic-assisted growth.

Mindbloom's AI Copilot: Integrated into Mindbloom's at-home ketamine therapy program, the AI copilot helps clients set pretrip intentions, process post-trip emotions, and stay grounded between sessions. It generates custom reflections and visual art based on voice journals, aiming to enhance the therapeutic journey even outside of human-guided sessions. The company plans to evolve the tool into a real-time, intelligent assistant capable of interacting more dynamically with users.

Orb AI/Shaman Concepts (Speculative): Conceptual "orb" interfaces imagine an AI-powered, shaman-like robot facilitating various aspects of psychedelic therapy, from intake to trip navigation. While still speculative, such designs hint at a future where AI plays a central, embodied role in guiding altered states. These ideas raise provocative ethical and safety questions about replacing human presence with machines in deeply vulnerable psychological contexts.

AI in Virtual Reality and Brain Modulation Systems: Researchers are exploring how AI could coordinate immersive virtual reality environments and brain-modulating devices to enhance psychedelic therapy. These systems would respond to real-time emotional and physiological signals, using haptic suits and VR to deepen and personalize the psychedelic experience. Though still in the conceptual phase, this approach represents the fusion of biotech, immersive tech, and AI in pursuit of therapeutic transformation.

Google DeepMind's chief business officer says Alphabet's drug-discovery company Isomorphic Labs "is preparing to launch human trials of AI-designed drugs," according to a report in Fortune, "pairing cutting-edge AI with pharma veterans to design medicines faster, cheaper, and more accurately." "There are people sitting in our office in King's Cross, London, working, and collaborating with AI to design drugs for cancer," said Colin Murdoch [DeepMind's chief business officer and president of Isomorphic Labs]. "That's happening right now."

After years in development, Murdoch says human clinical trials for Isomorphic's AI-assisted drugs are finally in sight. "The next big milestone is actually going out to clinical trials, starting to put these things into human beings," he said. "We're staffing up now. We're getting very close."

The company, which was spun out of DeepMind in 2021, was born from one of DeepMind's most celebrated breakthroughs, AlphaFold, an AI system capable of predicting protein structures with a high level of accuracy. Interactions of AlphaFold progressed from being able to accurately predict individual protein structures to modeling how proteins interact with other molecules like DNA and drugs. These leaps made it far more useful for drug discovery, helping researchers design medicines faster and more precisely, turning the tool into a launchpad for a much larger ambition... In 2024, the same year it released AlphaFold 3, Isomorphic signed major research collaborations with pharma companies Novartis and Eli Lilly. A year later, in April 2025, Isomorphic Labs raised $600 million in its first-ever external funding round, led by Thrive Capital. The deals are part of Isomorphic's plan to build a "world-class drug design engine..."

Today, pharma companies often spend millions attempting to bring a single drug to market, sometimes with just a 10% chance of success once trials begin. Murdoch believes Isomorphic's tech could radically improve those odds. "We're trying to do all these things: speed them up, reduce the cost, but also really improve the chance that we can be successful," he says. He wants to harness AlphaFold's technology to get to a point where researchers have 100% conviction that the drugs they are developing are going to work in human trials. "One day we hope to be able to say — well, here's a disease, and then click a button and out pops the design for a drug to address that disease," Murdoch said. "All powered by these amazing AI tools."

"Scientists have created the first lasers made entirely from edible materials," reports Science magazine "which could someday help monitor and track the properties of foods and medications with sensors that can be harmlessly swallowed." [The researchers' report] shows that tiny droplets of everyday cooking oils can act like echo chambers of light, otherwise known as lasers. By providing the right amount of energy to an atom, the atom's electrons will excite to a higher energy level and then relax, releasing a photon of light in the process. Trap a cloud of atoms in a house of mirrors and blast them with the right amount of energy, and the light emitted by one excited atom will stimulate one of its neighbors, amplifying the atoms' collective glow...

[The researchers] shot purple light at droplets of olive oil, whose surfaces can keep photons of light bouncing around, trapping them in the process. This reflected light excited the electrons in the oil's chlorophyll molecules, causing them to emit photons that triggered the glow of other chlorophyll molecules — transforming the droplet into a laser. The energy of the chlorophyll's radiation depends on the oil droplets' size, density, and other properties. The study's authors suggest this sensitivity can be exploited to track different properties of food or pharmaceutical products.

When researchers added oil droplets to foods and then measured changes in the laser light the droplets emitted, they could reliably infer the foods' sugar concentration, acidity, exposure to high temperatures, and growth of microorganisms. They also used the lasers to encode information, with droplets of different diameters functioning like the lines of a barcode. By mixing in sunflower oil droplets of seven specific sizes — all less than 100 microns wide — the researchers encoded a date directly into peach compote: 26 April, 2017, the first international Stop Food Waste Day.
Thanks to long-time Slashdot reader sciencehabit for sharing the news.

alternative_right shares a report from ScienceAlert: The world's first commercial hybrid of silicon circuitry and human brain cells will soon be available for rent. Marketed for its vast potential in medical research, the biological machine, grown inside a British laboratory, builds on the Pong-playing prototype, DishBrain. Each CL1 computer is formed of 800,000 neurons grown across a silicon chip, and their life-support system. While it can't yet match the mind-blowing capabilities of today's most powerful computers, the system has one very significant advantage: it only consumes a fraction of the energy of comparable technologies.

AI centers now consume countries' worth of energy, whereas a rack of CL1 machines only uses 1,000 watts and is naturally capable of adapting and learning in real time. [...] When neuroscientist Brett Kagan and colleagues pitted their creation against equivalent levels of machine learning algorithms, the cell culture systems outperformed them. Users can send code directly into the synthetically supported system of neurons, which is capable of responding to electrical signals almost instantly. These signals act as bits of information that can be read and acted on by the cells. But perhaps the greatest potential for this biological and synthetic hybrid is as an experimental tool for learning more about our own brains and their abilities, from neuroscience to creativity. The first CL1 units will reportedly ship soon for $35,000 each. Remote access can apparently be rented for $300 per week.

Beeftopia shares a report from CBS News: The U.S. government is preparing to breed billions of flies and dump them out of airplanes over Mexico and southern Texas to fight a flesh-eating maggot. That sounds like the plot of a horror movie, but it is part of the government's plans for protecting the U.S. from a bug that could devastate its beef industry, decimate wildlife and even kill household pets. This weird science has worked well before.

The targeted pest is the flesh-eating larva of the New World Screwworm fly. The U.S. Department of Agriculture plans to ramp up the breeding and distribution of adult male flies -- sterilizing them with radiation before releasing them. They mate with females in the wild, and the eggs laid by the female aren't fertilized and don't hatch. There are fewer larvae, and over time, the fly population dies out. It is more effective and environmentally friendly than spraying the pest into oblivion, and it is how the U.S. and other nations north of Panama eradicated the same pest decades ago. Sterile flies from a factory in Panama kept the flies contained there for years, but the pest appeared in southern Mexico late last year. [...]

The USDA expects a new screwworm fly factory to be up and running in southern Mexico by July 2026. It plans to open a fly distribution center in southern Texas by the end of the year so that it can import and distribute flies from Panama if necessary. The New World screwworm fly is a tropical species, unable to survive Midwestern or Great Plains winters, so it was a seasonal scourge. Still, the U.S. and Mexico bred and released more than 94 billion sterile flies from 1962 through 1975 to eradicate the pest, according to the USDA. The numbers need to be large enough that females in the wild can't help but hook up with sterile males for mating. One biological trait gives fly fighters a crucial wing up: Females mate only once in their weekslong adult lives. "A similar approach to certain species of mosquito is being debated," adds Beeftopia. "The impact on ecosystems is unclear."

"Researchers are embarking on an ambitious project to construct human genetic material from scratch," reports the Guardian, "to learn more about how DNA works and pave the way for the next generation of medical therapies." Scientists on the Synthetic Human Genome (SynHG) project will spend the next five years developing the tools and knowhow to build long sections of human genetic code in the lab. These will be inserted into living cells to understand how the code operates.

Armed with the insights, scientists hope to devise radical new therapies for the treatment of diseases. Among the possibilities are living cells that are resistant to immune attack or particular viruses, which could be transplanted into patients with autoimmune diseases or with liver damage from chronic viral infections. "The information gained from synthesising human genomes may be directly useful in generating treatments for almost any disease," said Prof Jason Chin, who is leading the project at the MRC's Laboratory of Molecular Biology (LMB) in Cambridge...

For the SynHG project, researchers will start by making sections of a human chromosome and testing them in human skin cells. The project involves teams from the universities of Cambridge, Kent, Manchester, Oxford and Imperial College London... Embedded in the project is a parallel research effort into the social and ethical issues that arise from making genomes in the laboratory, led by Prof Joy Zhang at the University of Kent. "We're a little way off having anything tangible that can be used as a therapy, but this is the time to start the discussion on what we want to see and what we don't want to see," said Dr Julian Sale, a group leader at the LMB.

"A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of Type 1 diabetes," reports the New York Times.

"One year later, these 10 patients no longer need insulin. The other two patients need much lower doses." The experimental treatment, called zimislecel and made by Vertex Pharmaceuticals of Boston, involves stem cells that scientists prodded to turn into pancreatic islet cells, which regulate blood glucose levels. The new islet cells were infused and reached the pancreas, where they took up residence. The study was presented Friday evening at the annual meeting of the American Diabetes Association and published online by The New England Journal of Medicine...

Patients in the study began to need less insulin within a few months of being infused with new islet cells, and most stopped needing the hormone altogether at about six months [said Dr. Trevor Reichman, director of the pancreas and islet transplant program at University Health Network, a hospital in Toronto, and first author of the study]. He added that patients' episodes of hypoglycemia went away within the first 90 days of treatment.

If the study continues to show positive results, the company expects to submit an application to the FDA next year. "For the short term, this looks promising" for severely affected patients like those in the study," said Dr. Irl B. Hirsch, a diabetes expert at the University of Washington who was not involved in the study. But patients in the trial had to stay on drugs to prevent the immune system from destroying the new cells. Suppressing the immune system, he said, increases the risk of infections and, over the long term, can increase the risk of cancer... Patients may have to take the immunosuppressant drugs for the rest of their lives, the Vertex spokesperson said.

Longtime Slashdot reader fahrbot-bot shares a report from the Cool Down: A team of chemical engineers at the Massachusetts Institute of Technology has invented a new process to separate crude oil components, potentially bringing forward a replacement that can cut its harmful carbon pollution by 90%. The original technique, which uses heat to separate crude oil into gasoline, diesel, and heating oil, accounts for roughly 1% of all global energy consumption and 6% of dirty energy pollution from the carbon dioxide it releases.

"Instead of boiling mixtures to purify them, why not separate components based on shape and size?" said Zachary P. Smith, associate professor of chemical engineering at MIT and senior author of the study, as previously reported in Interesting Engineering. The team invented a polymer membrane that divides crude oil into its various uses like a sieve. The new process follows a similar strategy used by the water industry for desalination, which uses reverse osmosis membranes and has been around since the 1970s. [The membrane excelled in lab tests. It increased the toluene concentration by 20 times in a mixture with triisopropylbenzene. It also effectively separated real industrial oil samples containing naphtha, kerosene, and diesel.]

Space may be the perfect place to study cancer — and someday even treat it," writes Space.com: On Earth, gravity slows the development of cancer because cells normally need to be attached to a surface in order to function and grow. But in space, cancer cell clusters can expand in all directions as bubbles, like budding yeast or grapes, said Shay Soker, chief science program officer at Wake Forest's Institute for Regenerative Medicine. Since bubbles grow larger and more quickly in space, researchers can more easily test substances clinging to the edge of the larger bubbles, too. Scientists at the University of Notre Dame are taking advantage of this quirk to develop an in-space cancer test that needs just a single drop of blood. The work builds on a series of bubble-formation experiments that have already been conducted on the ISS. "If cancer screening using our bubble technology in space is democratized and made inexpensive, many more cancers can be screened, and everyone can benefit," said Tengfei Luo, a Notre Dame researcher who pioneered the technology, speaking to the ISS' magazine, Upward. "It's something we may be able to integrate into annual exams. It sounds far-fetched, but it's achievable...."

Chemotherapy patients could save precious time, too. In normal gravity, they typically have to spend a half-hour hooked up to a needle before the medicine begins to take effect, because most drugs don't dissolve easily in water. But scientists at Merck have discovered that, in space, their widely used cancer drug pembrolizumab, or Keytruda, can be administered through a simple injection, because large crystalline molecules that would normally clump together are suspended in microgravity... Someday, microgravity could even help patients recovering from surgery heal faster than they would on Earth, Soker added. "Wound healing in high pressure is faster. That's the hyperbaric treatment for wounds...."

For the Wake Forest experiment, which is scheduled to launch next spring, scientists will cut out two sections of a cancer tumor from around 20 patients. One sample will stay on Earth while the other heads to the ISS, with scientists observing the difference. The testing will be completed within a week, to avoid any interference from cosmic radiation. If successful, Soker said, it could set the stage for diagnostic cancer tests in space available to the general population — perhaps on a biomedical space station that could launch after the planned demise of the ISS. "Can we actually design a special cancer space station that will be dedicated to cancer and maybe other diseases?" Shoker asked, answering his question in the affirmative. "Pharmaceutical companies that have deep pockets would certainly support that program."

Anne Wojcicki, co-founder of 23andMe, has regained control of the bankrupt DNA-testing company after a nonprofit she controls outbid Regeneron Pharmaceuticals with a $305 million offer. The company filed for bankruptcy in March due to declining demand and fallout from a major 2023 data breach.

"The agreement with non-profit TTAM Research Institute is the result of a final round of bidding that occurred earlier today between TTAM and Regeneron Pharmaceuticals," the company said in a statement.

Since filing for bankruptcy in March, 23andMe has received data deletion requests from 1.9 million users -- around 15% of its customer base. That number was revealed by 23andMe's interim chief executive Joseph Selsavage during a House Oversight Committee hearing, during which lawmakers scrutinized the company's sale following an earlier bankruptcy auction. "The bankruptcy sparked concerns that the data of millions of Americans who used 23andMe could end up in the hands of an unscrupulous buyer, prompting customers to ask the company to delete their data," adds TechCrunch. From the report: Pharmaceutical giant Regeneron won the court-approved auction in May, offering $256 million for 23andMe and its banks of customers' DNA and genetic data. Regeneron said it would use the 23andMe data to aid the discovery of new drugs, and committed to maintain 23andMe's privacy practices. Truly deleting your personal genetic information from the DNA testing company is easier said than done. But if you were a 23andMe customer and are interested, MIT Technology Review outlines that steps you can take.

It's no longer a hypothetical question, writes the Washington Post. "In recent years, scientists have devised powerful genetic tools that may be able to eradicate mosquitoes and other pests once and for all."

But along with the ability to fight malaria, dengue, West Nile virus and other serious diseases, "the development of this technology also raises a profound ethical question: When, if ever, is it okay to intentionally drive a species out of existence...?" When so many wildlife conservationists are trying to save plants and animals from disappearing, the mosquito is one of the few creatures that people argue is actually worthy of extinction. Forget about tigers or bears; it's the tiny mosquito that is the deadliest animal on Earth. The human misery caused by malaria is undeniable. Nearly 600,000 people died of the disease in 2023, according to the World Health Organization, with the majority of cases in Africa... But recently, the Hastings Center for Bioethics, a research institute in New York, and Arizona State University brought together a group of bioethicists to discuss the potential pitfalls of intentionally trying to drive a species to extinction. In a policy paper published in the journal Science last month, the group concluded that "deliberate full extinction might occasionally be acceptable, but only extremely rarely..."

It's unclear how important malaria-carrying mosquitoes are to broader ecosystems. Little research has been done to figure out whether frogs or other animals that eat the insects would be able to find their meals elsewhere. Scientists are hotly debating whether a broader "insect apocalypse" is underway in many parts of the world, which may imperil other creatures that depend on them for food and pollination... Instead, the authors said, geneticists should be able to use gene editing, vaccines and other tools to target not the mosquito itself, but the single-celled Plasmodium parasite that is responsible for malaria. That invisible microorganism — which a mosquito transfers from its saliva to a person's blood when it bites — is the real culprit.
A nonprofit research consortium called Target Malaria has genetically modified mosquitoes in their labs (which get core funding from the Gates Foundation and from Open Philanthropy, backed by Facebook co-founder Dustin Moskovitz and his wife). ), and hopes to deploy them in the wild within five years...

An anonymous reader quotes a report from IEEE Spectrum: In a development straight out of science fiction, Australian startup Cortical Labs has released what it calls the world's first code-deployable biological computer. The CL1, which debuted in March, fuses human brain cells on a silicon chip to process information via sub-millisecond electrical feedback loops. Designed as a tool for neuroscience and biotech research, the CL1 offers a new way to study how brain cells process and react to stimuli. Unlike conventional silicon-based systems, the hybrid platform uses live human neurons capable of adapting, learning, and responding to external inputs in real time. "On one view, [the CL1] could be regarded as the first commercially available biomimetic computer, the ultimate in neuromorphic computing that uses real neurons," says theoretical neuroscientist Karl Friston of University College London. "However, the real gift of this technology is not to computer science. Rather, it's an enabling technology that allows scientists to perform experiments on a little synthetic brain."

The first 115 units will begin shipping this summer at $35,000 each, or $20,000 when purchased in 30-unit server racks. Cortical Labs also offers a cloud-based "wetware-as-a-service" at $300 weekly per unit, unlocking remote access to its in-house cell cultures. Each CL1 contains 800,000 lab-grown human neurons, reprogrammed from the skin or blood samples of real adult donors. The cells remain viable for up to six months, fed by a life-support system that supplies nutrients, controls temperature, filters waste, and maintains fluid balance. Meanwhile, the neurons are firing and interpreting signals, adapting from each interaction.

The CL1's compact energy and hardware footprint could make it attractive for extended experiments. A rack of CL1 units consumes 850-1,000 watts, notably lower than the tens of kilowatts required by a data center setup running AI workloads. "Brain cells generate small electrical pulses to communicate to a broader network," says Cortical Labs Chief Scientific Officer Brett Kagan. "We can do something similar by inputting small electrical pulses representing bits of information, and then reading their responses. The CL1 does this in real time using simple code abstracted through multiple interacting layers of firmware and hardware. Sub-millisecond loops read information, act on it, and write new information into the cell culture." The company sees CL1 as foundational for testing neuropsychiatric treatments, leveraging living cells to explore genetic and functional differences. "It allows people to study the effects of stimulation, drugs and synthetic lesions on how neuronal circuits learn and respond in a closed-loop setup, when the neuronal network is in reciprocal exchange with some simulated world," says theoretical neuroscientist Karl Friston of University College London. "In short, experimentalists now have at hand a little 'brain in a vat,' something philosophers have been dreaming about for decades."

There was excitement when biotech company Collosal announced genetically modified grey wolves (first hailed as a "de-extinction" of the Dire wolf species after several millennia). "But bioethicists and conservationists are expressing unease with the kind of scientific research," writes the Chicago Tribune. [Alternate URL here.] "Unfortunately, as clever as this science is ... it's can-do science and not should-do science," said Lindsay Marshall, director of science in animal research at Humane World for Animals, formerly the Humane Society of the U.S.... Ed Heist, a professor at Southern Illinois University and a conservation geneticist, said the news bothered him. "This is not conservation, but people conflate it," he said. "The point is entertainment...."

Naomi Louchouarn [program director of wildlife partnerships at Humane World for Animals], has dedicated her studies and research to the relationship between humans and animals, specifically carnivores like gray wolves. "The reason our current endangered species are becoming extinct is because we don't know how to coexist with them," she said. "And this doesn't solve that problem at all." Humans can treat the symptoms of wildlife conflict with "big, flashy silver bullets" and "in this case, advanced, inefficient science," she said, but the real solution is behavioral change. "Assuming that we could actually bring back a full population of animals," Louchouarn said, "which is so difficult and so crazy — that's a big if — I don't understand the point of trying to bring back a woolly mammoth when we already can't coexist with elephants."
The article notes that even Colossal's chief science officer says their technology is at best one of several tools for fighting biodiversity loss, calling it a battle which humans are 'not close to winning'... We as a global community need to continue to invest in traditional approaches to conservation and habitat preservation, as well as in the protection of living endangered species."

But the article adds that the Trump administration "is citing the case of the dire wolf as it moves to reduce federal protections under the Endangered Species Act of 1973." (Wednesday U.S. interior secretary Doug Burgum has even posted on X "The concept of 'de-extinction' can serve as a bedrock for modern species conservation.")

And the article adds that "During a livestreamed town hall with Interior Department employees on April 9, Burgum said: "If we're going to be in anguish about losing a species, now we have an opportunity to bring them back. Pick your favorite species and call up Colossal. Ken Angielczyk, curator of mammal fossils at the Field Museum who researches extinct species that lived 200 to 300 million years ago, said it's a misguided approach. "If that's the basis ... for changing regulations related to the endangered species list, that is very, very premature," he said. "Because we can't resurrect things.... If the purpose is to restore the damage to the shared ecosystem, we have that opportunity right now," she said. "And that's the necessity immediately...."

"This whole idea that extinction is reversible is so dangerous," Marshall said, "because then it stops us caring."
Thanks to long-time Slashdot reader walterbyrd for sharing the news.

China is moving fast to dominate biotechnology, and the U.S. risks falling behind permanently unless it takes action over the next three years, a congressional commission said. WSJ: Congress should invest at least $15 billion to support biotech research over the next five years and take other steps to bolster manufacturing in the U.S., while barring companies from working with Chinese biotech suppliers, the National Security Commission on Emerging Biotechnology said in a report Tuesday. To achieve its goals, the federal government and U.S.-based researchers will also need to work with allies and partners around the world.

"China is quickly ascending to biotechnology dominance, having made biotechnology a strategic priority for 20 years," the commission said. Without prompt action, the U.S. risks "falling behind, a setback from which we may never recover." The findings convey the depth of worry in Washington that China's rapid biotechnology advances jeopardize U.S. national security. Yet translating the concern into tangible actions could prove challenging.

[...] China plays a large role supplying drug ingredients and even some generic medicines to the U.S. For years, it produced copycat versions of drugs developed in the West. Recent years have seen it become a formidable hub of biotechnology innovation, after the Chinese government gave priority to the field as a critical sector in China's efforts to become a scientific superpower.

An anonymous reader quotes a report from 404 Media: The creator of an open source genetic database is shutting it down and deleting all of its data because he has come to believe that its existence is dangerous with "a rise in far-right and other authoritarian governments" in the United States and elsewhere. "The largest use case for DTC genetic data was not biomedical research or research in big pharma," Bastian Greshake Tzovaras, the founder of OpenSNP, wrote in a blog post. "Instead, the transformative impact of the data came to fruition among law enforcement agencies, who have put the genealogical properties of genetic data to use."

OpenSNP has collected roughly 7,500 genomes over the last 14 years, primarily by allowing people to voluntarily submit their own genetic information they have downloaded from 23andMe. With the bankruptcy of 23andMe, increased interest in genetic data by law enforcement, and the return of Donald Trump and rise of authoritarian governments worldwide, Greshake Tzovaras told 404 Media he no longer believes it is ethical to run the database. "I've been thinking about it since 23andMe was on the verge of bankruptcy and been really considering it since the U.S. election. It definitely is really bad over there [in the United States]," Greshake Tzovaras told 404 Media. "I am quite relieved to have made the decision and come to a conclusion. It's been weighing on my mind for a long time."

Greshake Tzovaras said that he is proud of the OpenSNP project, but that, in a world where scientific data is being censored and deleted and where the Trump administration has focused on criminalizing immigrants and trans people, he now believes that the most responsible thing to do is to delete the data and shut down the project. "Most people in OpenSNP may not be at particular risk right now, but there are people from vulnerable populations in here as well," Greshake Tzovaras said. "Thinking about gender representation, minorities, sexual orientation -- 23andMe has been working on the whole 'gay gene' thing, it's conceivable that this would at some point in the future become an issue." "Across the globe there is a rise in far-right and other authoritarian governments. While they are cracking down on free and open societies, they are also dedicated to replacing scientific thought and reasoning with pseudoscience across disciplines," Greshake Tzovaras wrote. "The risk/benefit calculus of providing free & open access to individual genetic data in 2025 is very different compared to 14 years ago. And so, sunsetting openSNP -- along with deleting the data stored within it -- feels like it is the most responsible act of stewardship for these data today."

"The interesting thing to me is there are data preservation efforts in the U.S. because the government is deleting scientific data that they don't like. This is approaching that same problem from a different direction," he added. "We need to protect the people in this database. I am supportive of preserving scientific data and knowledge, but the data comes second -- the people come first. We prefer deleting the data."

An anonymous reader shared this report from the Mercury News: After a year of fastidious planning, a microscopic sample of the ultra-rare radioactive element berkelium arrived at a Berkeley Lab. With just 48 hours to experiment before it would become unusable, a group of nearly 20 researchers focused intently on creating a brand-new molecule. Using a chemical glove box, a polycarbonate glass box with protruding gloves that shields substances from oxygen and moisture, scientists combined the berkelium metal with an organic molecule containing only carbon and hydrogen to create a chemical reaction... [Post-doc researcher Dominic] Russo, researcher Stefan Minasian, and 17 other scientists at Lawrence Berkeley National Laboratory had created berkelocene, a new molecule that usurps theorists' expectations about how carbon bonds with heavy-metal elements.

In the future, berkelocene may help humanity safely dispose of nuclear waste, according to a study published in the academic journal Science... The new molecular structure is, in the nomenclature of researchers, a "sandwich." In this formation, a berkelium atom, serving as the filling, lays in between two 8-membered carbon rings — the "bread" — and resembles an atomic foot-long sub. "It has this very symmetric geometry, and it's the first time that that's been observed," Minasian said.
The researchers believe more accurate models for how actinide elements like uranium behave will help solve problems related to long-term nuclear waste storage.

In an op-ed for MIT Technology Review, authors Carsten T. Charlesworth, Henry T. Greely, and Hiromitsu Nakauchi make the case for human "bodyoids" that could reduce animal testing, improve drug development, and alleviate organ shortages: Why do we hear about medical breakthroughs in mice, but rarely see them translate into cures for human disease? Why do so few drugs that enter clinical trials receive regulatory approval? And why is the waiting list for organ transplantation so long? These challenges stem in large part from a common root cause: a severe shortage of ethically sourced human bodies. It may be disturbing to characterize human bodies in such commodifying terms, but the unavoidable reality is that human biological materials are an essential commodity in medicine, and persistent shortages of these materials create a major bottleneck to progress.

This imbalance between supply and demand is the underlying cause of the organ shortage crisis, with more than 100,000 patients currently waiting for a solid organ transplant in the US alone. It also forces us to rely heavily on animals in medical research, a practice that can't replicate major aspects of human physiology and makes it necessary to inflict harm on sentient creatures. In addition, the safety and efficacy of any experimental drug must still be confirmed in clinical trials on living human bodies. These costly trials risk harm to patients, can take a decade or longer to complete, and make it through to approval less than 15% of the time.

There might be a way to get out of this moral and scientific deadlock. Recent advances in biotechnology now provide a pathway to producing living human bodies without the neural components that allow us to think, be aware, or feel pain. Many will find this possibility disturbing, but if researchers and policymakers can find a way to pull these technologies together, we may one day be able to create "spare" bodies, both human and nonhuman. These could revolutionize medical research and drug development, greatly reducing the need for animal testing, rescuing many people from organ transplant lists, and allowing us to produce more effective drugs and treatments. All without crossing most people's ethical lines.

Although it may seem like science fiction, recent technological progress has pushed this concept into the realm of plausibility. Pluripotent stem cells, one of the earliest cell types to form during development, can give rise to every type of cell in the adult body. Recently, researchers have used these stem cells to create structures that seem to mimic the early development of actual human embryos. At the same time, artificial uterus technology is rapidly advancing, and other pathways may be opening to allow for the development of fetuses outside of the body. Such technologies, together with established genetic techniques to inhibit brain development, make it possible to envision the creation of "bodyoids" -- a potentially unlimited source of human bodies, developed entirely outside of a human body from stem cells, that lack sentience or the ability to feel pain.

An anonymous reader quotes a report from 404 Media: 23andMe filed for Chapter 11 bankruptcy Sunday, leaving the fate of millions of people's genetic information up in the air as the company deals with the legal and financial fallout of not properly protecting that genetic information in the first place. The filing shows how dangerous it is to provide your DNA directly to a large, for-profit commercial genetic database; 23andMe is now looking for a buyer to pull it out of bankruptcy. 23andMe said in court documents viewed by 404 Media that since hackers obtained personal data about seven million of its customers in October 2023, including, in some cases "health-related information based upon the user's genetics," it has faced "over 50 class action and state court lawsuits," and that "approximately 35,000 claimants have initiated, filed, or threatened to commence arbitration claims against the company." It is seeking bankruptcy protection in part to simplify the fallout of these legal cases, and because it believes it may not have money to pay for the potential damages associated with these cases.

CEO and cofounder Anne Wojcicki announced she is leaving the company as part of this process. The company has the genetic data of more than 15 million customers. According to its Chapter 11 filing, 23andMe owes money to a host of pharmaceutical companies, pharmacies, artificial intelligence companies (including a company called Aganitha AI and Coreweave), as well as health insurance companies and marketing companies. Shortly before the filing, California Attorney General Rob Bonta issued an "urgent" alert to 23andMe customers: "Given 23andMe's reported financial distress, I remind Californians to consider invoking their rights and directing 23andMe to delete their data and destroy any samples of genetic material held by the company."

In a letter to customers Sunday, 23andMe said: "Your data remains protected. The Chapter 11 filing does not change how we store, manage, or protect customer data. Our users' privacy and data are important considerations in any transaction, and we remain committed to our users' privacy and to being transparent with our customers about how their data is managed." It added that any buyer will have to "comply with applicable law with respect to the treatment of customer data."

404 Media's Jason Koebler notes that "there's no way of knowing who is going to buy it, why they will be interested, and what will become of its millions of customers' DNA sequences. 23andMe has claimed over the years that it strongly resists law enforcement requests for information and that it takes customer security seriously. But the company has in recent years changed its terms of service, partnered with big pharmaceutical companies, and, of course, was hacked."